阿糖胞苷HepDirect前药MB07133的波谱特征与晶体结构
收稿日期: 2014-08-27
修回日期: 2015-07-24
网络出版日期: 2015-09-05
NMR Characteristics and Crystal Structure of Cytarabine HepDirect Prodrug MB07133
Received date: 2014-08-27
Revised date: 2015-07-24
Online published: 2015-09-05
王明 , 王民昌* , 赵小璟 , 苏鹏飞 , 潘清 , 陈智群 , 李晓宇 . 阿糖胞苷HepDirect前药MB07133的波谱特征与晶体结构[J]. 波谱学杂志, 2015 , 32(3) : 518 -527 . DOI: 10.11938/cjmr20150313
The structure of the title compound (MB07133) was determined by one-dimensional (i.e., 1H and 13C NMR) and two-dimensional (i.e., 1H-1H COSY, gHSQC and gHMBC) NMR techniques. The 1H and 13C NMR chemical shifts were assigned. The crystal structure of the compound was determined using X-ray single crystal diffraction. The spectral feature and crystal structure of the compound, as well as the structure-function relationship with respective to its use as a prodrug, were discussed.
[1] Boyer, Serge H, Sun Z L, et al. Gomez D arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma[J]. J Med Chem, 2006, 49(26): 7 711－7 720.
[2] Hecker S J, Erion M D. Prodrugs of phosphates and phosphonates[J]. J Med Chem, 2008, 51: 2 328－2 345.
[3] MacKenna, Deidre A, Montag, et al. Delivery of high levels of anti-proliferative nucleoside triphosphates to CYP3A-expressing cells as a potential treatment for hepatocellular carcinoma[J]. Cancer Chemoth Pharm, 2009, 64(5): 981－991.
[4] Erion Mark D, Van Poelje, Paul D, et al. Liver-targeted drug delivery using HepDirect prodrugs[J]. J Pharm Exp Ther, 2005, 312(2): 554－560.
[5] Schultz C. Prodrugs of biologically active phosphate esters[J]. Bioorg Med Chem, 2003, 11: 885－898.
[6] Krise J P, Stella V J. Prodrugs of phosphates, phosphonates, and phosphinates[J]. Adv Drug Deliv-Rev, 1996, 19: 287－310.
[7] Sofia M J, Bao D, Chang W, et al. Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug(PSI-7977) for the treatment of hepatitis C virus[J]. J Med Chem, 2010, 53: 7 202－7 218.
[8] Dang Q, Kasibhatla S R, Jiang T, et al. Discovery of phosphonic diamide prodrugs and their use for the oral delivery of a series of fructose 1,6-bisphosphatase inhibitors[J]. J Med Chem, 2008, 51: 4 331－4 339.
[9] Siddiqui A Q, McGuigan C, Ballatore C, et al. Design and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture: structural determinants for in vitro activity and QSAR[J]. J Med Chem, 1999, 42: 4 122－4 128.
[10] Zhu Z J, Chen H G, Goel O P, et al. Phosphate prodrugs of PD154075[J]. Bioorg Med Chem Lett, 2000, 10: 1 121－1 124.
[11] Chen Yue(陈玥), Li Jian-feng(李剑峰), Wei Ya-bing(韦亚兵), et al. Spectral data deduced structure of new drug lomerizine dihydrochloride(新药盐酸洛美利嗪的波谱特征与结构确证)[J]. Chinese J Magn Reson(波谱学杂志), 2006, 23(3): 341－348.
[12] Zhang Pei-xuan(张佩璇), Li Jian-feng(李剑峰), Wei Ya-bing(韦亚兵), et al. NMR characterization and structural elucidation of fluorine derivative of tetrahydroberberine(氟代四氢小檗碱的波谱特征与结构解析)[J]. Chinese J Magn Reson(波谱学杂志), 2009, 26(1): 111－119.
[13] Erion M D, Reddy K R, Boyer S H, et al. Design, synthesis, and characterization of a series of cytochrome P450 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver[J]. J Am Chem Soc, 2004, 126: 5 154－5 163.
[14] Moosavi-Movahedi A A, Hakimelahi S, Chamani J, et al. Design, synthesis, and anticancer activity of phosphonic acid diphosphate derivative of adenine-containing butenolide and its water-soluble derivatives of paclitaxel with high antitumor activity[J]. Bioorg Med Chem, 2003, 11: 4 303－4 313.
[15] Erion M D, Van Poelje, Mackenna D A, et al. L iver-targeted drug delivery us ing hepDirect prodrugs[J]. J Pharm Exp Ther, 2005, 312(2): 554－560.
[16] Boyer S H, Sun Z, Jiang H J, et al. Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-β-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma[J]. J Med Chem, 2006, 49(26): 7 711－7 720.
/
| 〈 |
|
〉 |